EMGM website back to homepage

PROGRAMME

Preliminary Programme Overview

 

Preliminary Detailed Scientific Programme


Monday 18 September

16:00–18:00   Arrival and registration
 
18:00–21:00
 
Welcome session
18:00–19:00     Welcome reception  
19:00–19:30     ECDC talk  
19:30–20:00     Recent changes in meningococcal epidemiology in Australia and implementation of a population study to investigate the impact of MenB vaccination on meningococcal carriage in South Australian adolescents
Helen Marshall, Adelaide, Australia
 
20:00–20:30     Discussion  
20:30–21:00     Informal gathering continued  
 
 

Tuesday 19 September

08:00–16:30   Registration
 
08:30–09:00
 
Welcome Address
  • Ulrich Vogel, EMGM President
  • Pavla Krizova, EMGM 2017 Chair
  • Chris Head, CoMo President
 
09:00–10:15
 
Oral session 1: Epidemiology of invasive meningococcal and Haemophilus influenzae disease

Moderators: Martin Maiden & Paula Mölling

09:00–09:15     Whole genome sequencing of the emerging invasive Neisseria meningitidis serogroup W in Sweden
Lorraine Eriksson, Örebro, Sweden
   O1.01
(ID 24)
09:15–09:30     Development of EMERT II – European Meningococcal Epidemiology in Real Time: the genomic era
Keith A Jolley, Oxford, UK
   O1.02
(ID 26)
09:30–09:45     Abdominal presentation of invasive meningococcal infections: an underestimated diagnosis
Tamazoust Guiddir, Paris, France
   O1.03
(ID 45)
09:45–10:00     Meningococcal B vaccination and its possible implementation into national immunization calendar in the Czech Republic
Roman Prymula, Hradec Kralove, Czech Republic
   O1.04
(ID 70)
10:00–10:15     Long-term mortality after invasive NTHi infection
Sarah Collins, London, UK
   O1.05
(ID 83)
 
10:15–10:45   Coffee break
 
10:45–12:15
 
Oral session 2: Strain characterization and antibiotic resistance of Neisseria meningitidis and Haemophilus influenzae

Moderators: Arie van der Ende & Pavla Krizova

10:45–11:00     Fifteen years of antimicrobial susceptibility surveillance of invasive meningococcal isolates in Germany
Heike Claus, Würzburg, Germany
   O2.01
(ID 69)
11:00–11:15     Characterisation of meningococcal isolates responsible for invasive meningococcal disease in patients with terminal complement pathway deficiencies
Muhamed-Kheir Taha, Paris, France
   O2.02
(ID 51)
11:15–11:30     Emergence of meningococci with reduced susceptibility to third-generation cephalosporins
Ala-Eddine Deghmane, Paris, France
   O2.03
(ID 47)
11:30–11:45     Invasive meningococcal disease: clinical and microbiological analysis
Olga Dzupova, Prague, Czech Republic
   O2.04
(ID 18)
11:45–12:00     Development of Bexsero® outer membrane vesicle typing system for analysis of meningococcal whole genome sequences
Charlene Rodrigues, Oxford, UK
   O2.05
(ID 64)
12:00–12:15     Imipenem susceptibility in invasive H. influenzae isolates in Germany 2016
Thien-Tri Lam, Würzburg, Germany
   O2.06
(ID 25)
 
12:15–13:30   Lunch break and poster viewing
 
13.30–14:00
 
Oral session 3: Public Health Management

Moderators: Dominique Caugant & Maria João Simões

13:30–13:45     Revised Guidance for the Evaluation and Public Health Management of Suspected Outbreaks of Meningococcal Disease in the United States
Sarah A Meyer, Atlanta, USA
   O3.01
(ID 59)
13:45–14:00     Pre-hospital antibiotics in meningococcal disease: Methods for robust analysis of surveillance data to guide public health management
Amanda Kvalsvig, Wellington, New Zealand
   O3.02
(ID 44)
 
14:00–15:15
 
Pfizer Satellite Symposium: Preventing MenB by targeting fHBP, a meningococcal protein critical to immune evasion

Chair: Paul Balmer

14:00–14:05     Welcome & Introduction
Paul Balmer, Pfizer
 
14:05–14:35     Role of the polysaccharide capsule and factor H binding protein in protecting Neisseria meningitidis from the immune system
Jamie Findlow, Pfizer
 
14:35–15:05     Trumenba: vaccine development, mechanism of action and clinical data of a bivalent factor H binding protein vaccine
Bernard Fritzell, BFL Consulting, Jau-Dignac-et-Loirac, France
 
15:05–15:15     Concluding Remarks and Q&A
Paul Balmer, Pfizer
 
 
15:15–16:45   Coffee break and poster viewing
 
16:45–18:00
 
Oral session 4: Laboratory surveillance by molecular techniques of invasive meningococcal and Haemophilus influenzae disease

Moderators: Thien-Tri Lam & Ala-Eddine Deghmane

16:45–17:00     Invasive Neisseria meningitidis Population Structure Ten Years After Recommended Use of the Quadrivalent Meningococcal Conjugate Vaccine in the United States
Caelin Potts, Atlanta, USA
   O4.01
(ID 50)
17:00–17:15     Distribution of 4CMenB, Bexsero®, vaccine antigenic variants in the United Kingdom, 2010/11–2015/16
Charlene MC Rodrigues, Oxford, UK
   O4.02
(ID 49)
17:15–17:30     Targeted DNA enrichment and whole genome sequencing of Neisseria meningitidis directly from clinical specimens
Stephen A Clark, Manchester, UK
   O4.03
(ID 3)
17:30–17:45     Evaluation of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry in identifying Neisseria species
Eva Hong, Paris, France
   O4.04
(ID 46)
17:45–18:00     Capsule loss in invasive Haemophilus influenzae serotype b.
Kenneth Meyler, Dublin, Ireland
   O4.05
(ID 4)
 
18:30
 
EMGM General Assembly
 
 

Wednesday 20 September

08:00–16:30   Registration
 
08:30–09:15
 
Oral session 5: Carriage dynamics in meningococci and Haemophilus influenzae

Moderators: Georgina Tzanakaki & Robert Mulhall

08:30–08:45     Risk Factors for Carriage of Neisseria meningitidis in British Teenagers associated with changing disease incidence
Jenny M. MacLennan, Oxford, UK
   O5.01
(ID 61)
08:45–09:00     Whole genome sequencing reveals within-host genetic changes in paired meningococcal carriage isolates from Ethiopia
Guro K Bårnes, Oslo, Norway
   O5.02
(ID 21)
09:00–09:15     Capsule genes are common among Neisseria commensals
Marianne Clemence, Oxford, UK
   O5.03
(ID 41)
 
09:15–10:15   Coffee break
 
10:15–12:15
 
Workshop 1: Increased incidence of invasive meningococcal disease due to serogroup W in Europe and Chile: Epidemiology, genomic analysis and impact of MenACWY vaccines

Conveners: Wiebke Hellenbrand & Shamez Ladhani

10:15–10:20     Brief overview of MenWCY epidemiology and vaccination recommendations in European countries
Wiebke Hellenbrand, Berlin, Germany
 
10:20–10:35     Increase in invasive serogroup W meningococcal disease since 2015 in the Netherlands
Mirjam J Knol, Bilthoven, the Netherlands
   W1.02
(ID 56)
10:35–10:45     Clonal replacement and expansion within invasive isolates of serogroup W in France
Anne-Sophie Barret, Saint Maurice, France
   W1.03
(ID 48)
10:45–10:55     Increase of serogroup W meningococcal invasive strains in Spain: Genomic analysis
Raquel Abad, Majadahonda, Spain
   W1.04
(ID 42)
10:55–11:05     Laboratory surveillance of serogroup W meningococcal disease in Germany
Heike Claus, Würzburg, Germany
   W1.05
(ID 68)
11:05–11:20     Chilean experience with serogroup W outbreak and meningococcal ACWY conjugate vaccines
Rodolfo Villena, Santiago, Chile
   W1.06
(ID 35)
11:20–11:40     Increased incidence of serogroup W IMD in England and impact of MenACWY vaccination programme in adolescents
Helen Campbell, London, UK
 
11:40–12:15     Panel discussion: Implications of the MenW increase for meningococcal vaccination strategies in European countries  
 
12:15–13:15   Lunch break
 
13:15–14:30
 
Workshop 2: Meningococcal disease and complement deficiency

Conveners: Ian Feavers & Ray Borrow

13:15–13:35     The action of Eculizumab and experience of managing patients on this therapy
Alexander Röth, Essen, Germany
 
13:35–13:55     Immune responses to meningococcal vaccination in patients on Eculizumab therapy
Stephen Hughes, Manchester, UK
 
13:55–14:15     The genetic basis of different late complement component deficiencies patients and the genetic characteristics of their invasive meningococcal strains
Muhamed-Kheir Taha, Paris, France
 
14:15–14:30     Feedback from the EMGM complement deficiency questionnaire
Ray Borrow, Manchester, UK
 
 
14:30–15:15   Coffee break
 
15:15–16:35
 
Oral session 6: Vaccine implementation and new vaccines

Moderators: Julio Vazquez & Anna Skoczynska

15:15–15:30     Enhanced surveillance of invasive meningococcal disease following introduction of 4CMenB (Bexsero) into the UK infant vaccination schedule; what can the laboratory data tell us?
Jay Lucidarme, Manchester, UK
   O6.01
(ID 77)
15:30–15:45     A global assessment of Bexsero strain coverage: comparative analysis of MATS and antigen genotyping
Alessandro Muzzi, Siena, Italy
   O6.02
(ID 43)
15:45–16:00     Trumenba® Elicits Bactericidal Antibodies Against Non-Serogroup B Meningococci
Thomas R Jones, Pearl River, USA
   O6.03
(ID 1)
16:00–16:20     A Bivalent Meningococcal B Vaccine Elicits Robust Bactericidal Responses in Adolescents and Young Adults against Diverse Meningococcal B Strains / Persistence and 4-Year Boosting of the Bactericidal Response Elicited by 2- and 3-Dose Schedules of MenB-FHbp
Johannes Beeslaar, Hurley, UK
   O6.04
(ID 66/67)
16:20–16:35     Vaccine effectiveness against Haemophilus influenzae serotype b disease following introduction of Hepatitis B containing vaccine in the Netherlands
Mirjam J Knol, Bilthoven, the Netherlands
   O6.05
(ID 58)
 
16:35–17:30   Poster viewing
 
17:30–18:00
 
GSK Satellite Symposium: Development and international use of 4CMenB
17:30–17:42     Development and introduction of 4CMenB
Angelika Banzhoff, GSK
 
17:42–17:54     Use of 4CMenB in Saguenay-Lac St. Jean, a region of Quebec, Canada
Veronique Abitbol, GSK
 
17:54–18:00     Q&A  
 
18:45   Departure for Dinner by bus from the Diplomat Hotel
 
 

Thursday 21 September

08:00–14:00   Registration
 
08:30–09:45
 
Workshop 3: Atypical manifestations of meningococcal and Haemophilus influenzae disease

Convener: Muhamed-Kheir Taha

08:30–08:35     Introduction
Muhamed-Kheir Taha, Paris, France
 
08:35–09:20     Short communications from the reference centres (Nm and Hi) in selected European countries
Heads of selected reference centres (Nm and Hi)
 
09:20–09:35     A global discussion
09:35–09:45     A short conclusion
Muhamed-Kheir Taha, Paris, France
 
 
09:45–10:15   Coffee break
 
10:15–12:15
 
Workshop 4: Experience with MenB vaccination: Update on vaccine effectiveness and impact, safety, vaccination strategies and future outlook

Conveners: Shamez Ladhani & Wiebke Hellenbrand

10:15–10:20     Brief overview of MenB epidemiology and vaccination recommendations in European countries
Wiebke Hellenbrand, Berlin, Germany
 
10:20–10:35     Update on effectiveness and impact of Bexsero vaccination in infants in England
Sydel R Parikh, London, UK
   W4.02
(ID 86)
10:35–11:05     Update on Safety of Bexsero:  
10:35–10:50     Active and passive postmarketing surveillance “Bexsero vaccine safety – the UK experience”
Philip Bryan, London, UK
 
10:50–11:05     Presentation to ED, primary care and hospitals after Bexsero vaccination
Shamez Ladhani, London, UK
 
11:05–11:35     Experience with MenB vaccination in other countries:  
11:05–11:20     The developments in the epidemiological situation of invasive meningococcal diseases in the West Bohemian region and the current options for vaccination
Petr Pazdiora, Pilsen, Czech Republic
   W4.05
(ID 34)
11:20–11:35     Implementation of MenB vaccination in Italy
Paola Stefanelli, Rome, Italy
 
11:35–11:50     Comparative overview of Trumenba® and Bexsero®: Composition, strain coverage, immunogenicity, potential herd protection, safety and impact in adolescents and adults
Wiebke Hellenbrand, Berlin, Germany
 
11:50–12:15     Panel Discussion: Outlook for MenB vaccination  
 
12:15–13:15   Lunch break
 
13:15–14:15
 
Oral session 7: Vaccine implementation and new vaccines – 2

Moderators: Susanne Jakobsson & Jay Lucidarme

13:15–13:30     Impact of Meningococcal C vaccination in Germany
Wiebke Hellenbrand, Berlin, Germany
   O7.01
(ID 22)
13:30–13:45     Vaccine failures and vaccine effectiveness during the meningococcal C outbreak in Tuscany, 2015–2016
Giovanni Rezza, Roma, Italy
   O7.02
(ID 10)
13:45–14:00     Immune Persistence of MenA specific antibody in Ghanaian children more than five years after immunization with PsA-TT (2.5 µg, 5 µg, or 10 µg polysaccharide concentration)
Patrick O Ansah, Navrongo, Ghana
   O7.03
(ID 57)
14:00–14:15     MenAfriVac Immunogenicity and Micronutrient Status among Malian Children
Maria E Sundaram, Minneapolis, USA
   O7.04
(ID 63)
 
14:15
 
Closing Session
  • Presentation of venue for EMGM 2019
  • Paola Stefanelli, EMGM Vice-President

 

Last update on August 1, 2017